Send to

Choose Destination
Biomed Pharmacother. 2018 Dec;108:254-262. doi: 10.1016/j.biopha.2018.07.095. Epub 2018 Sep 14.

Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation.

Author information

Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan; Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan.
Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan.
Department of Nursing, Tzu Chi University of Science and Technology, Hualien, Taiwan; Institute of Radiological Research, Chang Gang University, Taoyuan, Taiwan.
Department of Nursing, Tzu Chi University of Science and Technology, Hualien, Taiwan.
Department of Chemistry, National Dong Hwa University, Hualien, Taiwan.
Institute of Neuroscience, Research Center for Mind, Brain & Learning, National Chengchi University, Taipei, Taiwan. Electronic address:


Parkinson's disease (PD) is a profound neurodegenerative disorder with gradual loss of dopamine nigrostriatal neurons linked to serious behavioral symptoms. While the current treatment strategies present limitations on halting the progression of PD, this study aimed to investigate the therapeutic potential of honokiol, as a partial peroxisome proliferator-activated receptor-gamma (PPARγ) mimic, on the proceeding behavioral and biochemical alterations in hemiparkinsonian mice. Results showed that unilateral striatal 6-hydroxydopamine (6-OHDA)-lesioned mice exhibited motor impairment, reflecting the contralateral rotation induced by apomorphine at 1-3 weeks post-lesion. Subchronic honokiol administration for 1-2 weeks, beginning 7 days after 6-OHDA-lesion, dose-dependently ameliorated motor dysfunction in hemiparkinsonian mice. Recovery of motor function was correlated with reversal of nigrostriatal dopaminergic neuronal loss, accompanied by higher tyrosine hydroxylase (TH) density, dopamine transporter (DAT) expression and vesicular monoamine transporter-2 (VMAT2) levels. Furthermore, honokiol attenuated oxidative stress and reactive astrocyte induction via decreasing NADPH-oxidase and glial fibrillary acidic protein (GFAP) expressions in 6-OHDA-lesioned striatum. The reversal effects of honokiol on behavioral impairment and striatal PPARγ expression were impeded by PPARγ antagonist GW9662. Notably, subchronic honokiol treatment extended the lifespan of these hemiparkinsonian mice. The present findings demonstrate the therapeutic activities of honokiol in ameliorating motor impairment and progressive dopaminergic damage that could be associated with regulating PPARγ signaling. Therefore, honokiol may potentially exert as a novel therapeutic candidate through PPARγ activation for management of motor symptoms and progressive neurodegeneration in PD.


6-Hydroxydopamine; Honokiol; PPARγ; Parkinson’s disease; Positron-emission tomography

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center